Blog

FSD Pharma Inc. Added to the CSE 25 Composite Index

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 18, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) has been added to the CSE 25 Composite Index, effective after the close on Friday, June 15, 2018. Continue Reading

FSD Pharma Inc. Announces Appointment of New Director

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 14, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company“) (CSE: HUGE), is pleased to announce the appointment of Mr. Anthony Durkacz to its Board of Directors, effective immediately. Continue Reading

FSD Pharma breaks all-time weekly volume trading record

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 7, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that in the first 5 consecutive days of trading, the company traded exactly 259,230,820 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). Continue Reading

FSD Pharma secures exclusive rights in Canada for line of proprietary products and premium access to cannabinoid science research platform in Israel


TORONTOJune 6, 2018 /CNW/ – FSD Pharma Inc. (the “Company”) (CSE: HUGE), is pleased to announce that its wholly- owned subsidiary FV Pharma Inc (“FV Pharma”) have entered into a strategic alliance with SciCann Therapeutics Inc. (“SciCann”) by executing a binding Memorandum of Understanding  (the “MOU“) dated May 28, 2018, Continue Reading

History Made, FSD Broke All-time Daily Volume Record

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

TORONTOMay 31, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that on its first day of trading (May 29, 2018) the company traded exactly 78,477,861 Class B subordinate voting shares on the CSE (Canadian Securities Exchange), 7,592,500 on AQC-Lit, 1,680,000 on AQC-Neo, 136,000 on CHIX, 236,500 on CX2 and 25,013,000 on the TriAct exchange for an aggregate total of 113,135,861 shares traded. This is the largest total quantity of share volume traded by a CSE listed issuer by over 27% above the recorded all-time high of 88,846,729, on the first day of trading, as confirmed by the CSE. Continue Reading

All-Time Daily Volume Record Broken and Thanks to All Shareholders

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOMay 30, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that on its first day of trading (May 29, 2018) the company traded exactly 78,477,861 Class B subordinate voting shares on the CSE (Canadian Securities Exchange), 7,592,500 on AQC-Lit, 1,680,000 on AQC-Neo, 136,000 on CHIX, 236,500 on CX2 and 25,013,000 on the TriAct exchange for an aggregate total of 113,135,861 shares traded. This is the largest total quantity of share volume traded by a CSE listed issuer by over 27% above the recorded all-time high of 88,846,729, on the first day of trading, as confirmed by the CSE. Continue Reading

FSD Pharma Inc. Commences Trading on Canadian Securities Exchange

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

TORONTOMay 29, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE), a Canadian cannabis company focused on building the world’s largest indoor hydroponic cultivation and processing facility through its wholly owned subsidiary FV Pharma Inc. (“FV”), a Licensed Producer (“LP”) pursuant to the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), is pleased to announce the company has commenced trading publicly on the Canadian Securities Exchange (“CSE”) under the symbol “HUGE”. Continue Reading

High Tide Closes Strategic Investment by FV Pharma

CALGARY, May 2, 2018 /CNW/ – High Tide Ventures Inc. (“High Tide” or the “Company”) today announced that it has completed and closed a non-brokered private placement offering (the “Offering”), pursuant to which the Company issued 3,705,000 common shares at a price of $1.00 per share for gross proceeds of $3,705,000. Among Continue Reading